Table 2.
Baseline patient characteristics, extent of exposure to difamilast ointment, and concomitant use of topical anti-inflammatory agents
| Adult patients (n = 166) | Pediatric patients (n = 200) | |
|---|---|---|
| Age, years, mean ± SD | 33.7 ± 11.3 | 7.4 ± 3.5 |
| Male | 101 (60.8) | 119 (59.5) |
| Years since onset of AD, mean ± SD | 24.7 ± 13.5 | 5.9 ± 3.5 |
| IGA score | ||
| IGA 2, mild disease | 51 (30.7) | 78 (39.0) |
| IGA 3, moderate disease | 102 (61.4) | 108 (54.0) |
| IGA 4, severe/very severe disease | 13 (7.8) | 14 (7.0) |
| Severity of ADa | ||
| Mild | 17 (10.2) | 31 (15.5) |
| Moderate | 91 (54.8) | 99 (49.5) |
| Severe | 45 (27.1) | 52 (26.0) |
| Very severe | 13 (7.8) | 18 (9.0) |
| EASI score, mean ± SD | 16.7 ± 10.6 | 12.6 ± 10.1 |
| Affected body surface area | ||
| ≥ 5% to < 10% | 12 (7.2) | 24 (12.0) |
| ≥ 10% to < 20% | 36 (21.7) | 57 (28.5) |
| ≥ 20% to < 40% | 62 (37.3) | 55 (27.5) |
| ≥ 40% | 56 (33.7) | 64 (32.0) |
| Exposure to difamilast ointment | ||
| Treatment period, days, mean ± SD | 274.5 ± 126.3 | 313.2 ± 96.7 |
| Total amount applied, g, mean ± SD | 1854.0 ± 1812.8 | 1332.8 ± 1141.0 |
| Amount applied per application, g, mean ± SD | 3.7 ± 2.9 | 2.3 ± 2.0 |
| Patients who used topical anti-inflammatory agents | 125 (75.3) | 150 (75.0) |
Data are number of patients (%) unless otherwise indicated
AD atopic dermatitis, EASI Eczema Area and Severity Index, IGA Investigator’s Global Assessment, SD standard deviation
aJapanese severity index of AD is based on the “Guidelines for the Treatment of Atopic Dermatitis 2008” by the Health and Labour Sciences Research